Chris BartonHead of US Characterization at Takeda
Chris Barton is the Head of Characterization in the US at Takeda Pharmaceutical Company Ltd, leading structural studies on biotherapeutics from research to commercial products. He received his doctorate at the University of Cambridge studying polysaccharide and glycoprotein biosynthesis and completed post‐doctoral training working in mass spectrometry at a UK anti‐doping laboratory. He has worked in biotherapeutic analytical and process development in a range of roles at Quotient Bioresearch, MedImmune (AstraZeneca), Merrimack and Shire Pharmaceuticals (now Takeda).
His role at Takeda is focused on developing the product understanding and tools to study a range of protein products. He has a special interest in non-platform modalities and the intersection between product understanding and process decisions. His research interests include developing tools for the analysis and understanding of protein glycosylation and post‐translational modification in cell culture.